68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

• Status: Not yet recruiting
• Trial end date: 2028-08-31
• Target enrollment: 0
• Participant gender: All

Summary

Somatostatin receptor (SSR) imaging is a critical component of clinical care for many patients being investigated for or with confirmed SSR positive tumors. In the past, 111In-octreotide imaging has been used for this purpose but it has been recently supplanted globally by SSR positron emission tomography (PET) imaging due to better image quality and higher diagnostic accuracy.

This study will assess the safety and diagnostic effectiveness of 68Ga-HA-DOTATATE produced a the Edmonton Radiopharmaceutical Centre (ERC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alberta

Criteria

Inclusion Criteria:

• Patients with known or clinically suspected somatostatin receptor positive tumors including but not limited to: gastrointestinal neuroendocrine tumors, pancreatic neuroendocrine tumors, pulmonary neuroendocrine tumors, neuroendocrine tumors - primary unknown, pheochromocytoma, paraganglioma, medullary thyroid cancer, medulloblastoma, meningioma

• A standard clinical CT or MRI is obtained within 6 months of enrollment

• Ability to provide written informed consent prior to participation in the study (participant or if required a legal medical decision maker)

Exclusion Criteria:

• Weight > 225 kg (weight limit of the PET/CT scanner)

• Inability to scan (ie. extreme claustrophobia) or inability to lie still for imaging

• Any additional medical condition, serious inter-current illness, or other extenuating circumstance that, in the opinion of the investigator or attending department physician, may significantly interfere with study performance or interpretation

• Previous allergic reaction to DOTATATE or somatostatin analogues

• Lack of intravenous access